AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: VABYSMO (Genentech) (vabysmo.com)
This is a high-substance, low-BS pharmaceutical asset that prioritizes regulatory compliance and clinical data over marketing air. While it employs standard patient-centric cliches, it anchors every emotional hook in rigid, quantitative clinical proof.
Replace the generic ‘Open Up Your World’ H3 headings with specific outcome headers like ‘Sustained Vision Gains over 12 Months.’ Provide direct links to peer-reviewed publications in the Lancet or NEJM rather than relying on ‘data on file’ for market share statistics. Add ClinicalTrials.gov identifiers (e.g., NCT numbers) directly next to clinical outcome summaries for maximum transparency. Ensure that the ‘data on file’ from June 2025 is updated as it approaches the ‘stale’ 12-month threshold relative to the current 2026 system date.
The site exhibits high information density with a low fluff-to-substance ratio. Headings such as ‘#1 PRESCRIBED FDA-APPROVED TREATMENT FOR WET AMD’ are supported by specific data sources like Verana Health patient share analysis (Apr-Jun 2025). Body text is saturated with quantitative clinical outcomes, such as gaining ‘5 letters at 1 month’ and ‘6 letters over 1 year,’ effectively avoiding vague power words in favor of measurable metrics.
A validator checks tags. An AI system checks whether your identity is stable across all crawl paths. Start your free canonical interpretation to see how your URLs are actually resolved by LLMs.
There is virtually zero semantic drift between pages. The homepage establishes VABYSMO as a treatment for wet AMD, DME, and RVO, and the sub-pages (specifically the WAMD page) provide deeper technical and clinical dives into those exact indications. The Spanish version maintains identical claims, ensuring cross-linguistic messaging consistency.
Our Authority as a Service model transforms raw diagnostic data into high stakes results. Start your Clinical Strategic Diagnosis for 1 Euro to secure the strategic fixes required for growth.
The site avoids trust theatre by prominently displaying ‘Important Safety Information’ and clearly labeling patient testimonials with ‘Actor portrayal’ and ‘Patient compensated by Genentech.’ While it cites ‘data on file’ for its market share claims, it backs efficacy claims with clinical study averages (e.g., gains of 5-13 letters), providing a high degree of transparency for a commercial medical site.
Proof density is extremely high. Every major efficacy claim is footnoted with clinical trial specifics, including letter gain counts, timeframes (1 month to 1 year), and patient population counts (e.g., ‘7 out of 664 patients’). The site provides a verifiable evidence path for nearly every assertion made in the hero sections.
To examine how structural entropy affects chunking and retrieval, review the Moz Semantic HTML audit. View the Moz Semantic HTML Audit for a complete example of heading logic, landmark integrity, and DOM depth diagnostics.
The primary industry cliché is the value proposition ‘Open Up Your World,’ which is a standard pharmaceutical trope found in many vision-related treatments. However, this is balanced by unique clinical differentiators like being the ‘only FDA-approved treatment thought to block 2 causes of vision loss (VEGF and Ang-2),’ which prevents the content from being entirely copy-pasteable onto a competitor site.
Authority is well-established through robust schema_json identifying the parent organization (Genentech) and detailed prescribing information. The absence of named individual experts (e.g., lead researchers) is standard for drug-branded sites, as the authority is derived from the FDA approval status rather than personal digital footprints.
There is no disconnect between marketing tone and demonstrated performance; the site repeatedly qualifies its vision-improvement claims with ‘on average’ and ‘similar to aflibercept 2 mg.’ These performance claims are directly tied to clinical trial results cited in the footer notes and safety sections.
Medical Devices, Pharma & Biotech BS: VABYSMO (Genentech) (vabysmo.com)
The content perfectly aligns with the Pharma & Biotech industry, characterized by heavy regulatory disclosure, clinical trial data citations, and a focus on therapeutic mechanisms of action. The use of ‘faricimab-svoa’ and detailed safety protocols confirms the pharmaceutical nature of the entity.
A page that loads perfectly for users can still return an empty shell to an AI crawler. Examine the Crawlability Technical Guide and understand why script free extraction is the real measure of visibility.
“The low BS score is driven by high specificity in performance claims and an absence of semantic drift. Minor points were deducted for the use of generic industry value prop cliches ('Open Up Your World') and the use of 'data on file' citations which are less transparent than public database links.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 26, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at VABYSMO (Genentech) to view the most current version of their content and see directly what the company offers.